Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/11/21
End: 02/09/23
Due: 02/09/24
Phase: N/A
Priority: Normal
Start: 12/20/18
End: 11/01/21
Due: 11/01/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | NCT04775680 | Adagene (Suzhou) Limited | user2@example.com | None | 2021-03-11 | 2023-02-09 | 2024-02-09 | - | - | 2025-07-14 |
| Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | NCT03802955 | Adagene (Suzhou) Limited | user2@example.com | None | 2018-12-20 | 2021-11-01 | 2022-11-01 | - | - | 2025-07-14 |